Market Research Logo

Global Cancer Supportive Care Market 2017-2021

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Table Categories of cancers
    • Table Various modes applied for treatment of cancer
    • Table Side effects of various cancer treatments
    • Table Major drug classes used as cancer supportive agents
  • Market landscape
    • Market overview
      • Table Global cancer supportive care market snapshot
    • Market size and forecast
      • Table Global cancer supportive care market 2016-2021 ($ billions)
      • Table Opportunity analysis in global cancer supportive care market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Key molecules in different stages of development
    • Table Key clinical trials
  • Market segmentation therapeutic area
    • Table Segmentation of global cancer supportive care market by therapeutic area 2016
    • Table Segmentation of global cancer supportive care market by therapeutic area 2016 and 2021
    • Chemotherapy-induced anemia
      • Table Symptoms of anemia
      • Table Types of anemia
      • Table Global cancer supportive care market for chemotherapy-induced anemia 2016-2021($ billions)
      • Table Types of cancers closely associated with anemia
      • Table Commonly used ESAs
      • Table Side effects associated with the usage of ESAs
    • Chemotherapy-induced neutropenia
      • Table Global cancer supportive care market for chemotherapy-induced neutropenia 2016-2021 ($ billions)
    • Cancer pain
      • Table Types of cancer pain
      • Table Global cancer supportive care market for cancer pain 2016-2021 ($ billions)
    • CINV
      • Table Global cancer supportive care market for CINV 2016-2021 ($ billions)
      • Table Major drug classes used for treatment of CINV
      • Table Analysis of global CINV drugs market
    • Others
      • Table Global cancer supportive care market for others 2016-2021 ($ billions)
      • Table Some of the other side effects of cancer treatment
      • Table Effect of cancer treatment leading to oral complications
  • Geographical segmentation
    • Table Segmentation of global cancer supportive care market by geography 2016 and2021
    • Table Segmentation of global cancer supportive care market by geography 2016-2021 ($billions)
    • Cancer supportive care market in Americas
      • Table Market scenario in Americas
      • Table Cancer supportive care market in Americas 2016-2021 ($ billions)
      • Table Top 10 types of cancers in US 2014 (per 100,000 people)
      • Table Cancer survivors in US: Statistics and estimations 2016 and 2026
      • Table Economic and healthcare expenditure snapshot of US 2014 and 2015 ($ billions)
      • Table Economic and healthcare snapshot of Canada 2016
      • Table New cases of cancer in Canada 2016
    • Cancer supportive care market in EMEA
      • Table Market scenario in EMEA
      • Table Cancer supportive care market in EMEA 2016-2021 ($ billions)
      • Table Economic and healthcare snapshot of European region 2014
      • Table Cancer death statistics in EU 2015
    • Cancer supportive care market in APAC
      • Table Market scenario in APAC
      • Table Cancer supportive care market in APAC 2016-2021 ($ billions)
      • Table Cancer facts in China 2015
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Cancer cases snapshot
      • Table Estimated investment in oncology in developed and developing countries 2017
      • Table Common side effects associated with treatment of cancer in traditional methods
      • Table General side effects of radiotherapy
      • Table Support care drugs and their effects
      • Table Demographic and economic snapshot of India and China 2014 and 2016
    • Market challenges
      • Table Factors contributing to high cost of cancer drugs
      • Table Effect of high cost of cancer drugs on cancer supportive care market
      • Table Top concerns of health insurance in US
  • Market trends
    • Advent of biosimilars in cancer-associated treatment
    • Outsourcing of biosimilars manufacturing activities
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global cancer supportive care market 2016
  • Key vendor analysis
    • Amgen
      • Table Amgen: Key highlights
      • Table Amgen: Strength assessment
      • Table Amgen: Strategy assessment
      • Table Amgen: Opportunity assessment
    • Helsinn Healthcare
      • Table Helsinn Healthcare: Key highlights
      • Table Helsinn Healthcare: Strength assessment
      • Table Helsinn Healthcare: Strategy assessment
      • Table Helsinn Healthcare: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Global Cancer Supportive Care Market 2017-2021

About Cancer Supportive Care

Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others.

Technavio’s analysts forecast the global cancer supportive care market to grow at a CAGR of 3.38% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer supportive care market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in cancer supportive care market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Cancer Supportive Care Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • Helsinn Healthcare
  • Johnson &Johnson
  • Merck
Other prominent vendors
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Heron Therapeutics
  • Kyowa Hakko Kirin
  • Novartis
  • TESARO
  • Teva Pharmaceutical Industries
Market driver
  • Large number of side effects associated with the cancer treatment
  • For a full, detailed list, view our report
Market challenge
  • Rising popularity of targeted therapies for the treatment of cancer in developed countries
  • For a full, detailed list, view our report
Market trend
  • Advent of biosimilars in cancer-associated treatment
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Cancer Supportive Care Market 2017-2021

Technavio recognizes the following companies as the key players in the global cancer supportive care market: Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck.

Other Prominent Vendors in the market are: F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is advent of biosimilars in cancer-associated treatment. The growing demand for quality care has led to the increased use of erythropoietin drugs for the treatment of chemotherapy-induced anemia. The majority of countries are under pressure to address this demand without increasing healthcare expenditure.”

According to the report, one driver in the market is large number of side effects associated with the cancer treatment. Progress in cancer treatment has come with several challenges that go beyond a cure. Morbidity and toxicities are among the few of the biggest hurdles faced by cancer patients while going through radiation therapy or chemotherapy. A large number of side effects are associated with the treatment of cancer. These have been a major challenge for the traditional cancer treatment market (radiation and chemotherapy). The main aim of cancer treatment is to get rid of the cancer cells.

Further, the report states that one challenge in the market is rising popularity of targeted therapies for the treatment of cancer in developed countries. The increasing preference of targeted therapies instead of chemotherapy drugs will hinder the growth prospects in the market. As there is an increased need to target-specific molecules that are responsible for the growth of cancer, the vendors are focusing on the development of targeted therapies, which are highly specific than the traditional chemotherapy drugs. Also, as chemotherapy drugs are associated with higher side effects, the researchers are extensively conducting R&D activities to understand the disease etiology better and develop novel treatments.

Companies Mentioned

Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;